Restoring the patency of the coronary vessels and providing the ischemic myocardium with reperfused blood can cause additional tissue damage. A key element of ischemia and reperfusion (I/R) injury and major determinant of the evolution of damage in the affected myocardium is the inflammatory response. The main objective of the study is to evaluate the efficacy of colchicine in reducing I/R injury by effectively modulating the inflammatory response in the reperfused myocardium.

Start Date01 Oct 2014

Sponsor / Collaborator

General Hospital G. Gennimatas

[+1]

NCT02019095

/ CompletedNot ApplicableIIT

Clinical and Biological Markers in Ventilator-associated Pneumonia and the Acute Respiratory Distress Syndrome

In a recent experimental study, the investigators showed that the growth factor Activin A is expressed in the lungs of rats with the acute respiratory distress syndrome (ARDS) at levels that are comparable with those determined in the bronchoalveolar (BAL) lavage fluid from patients with ARDS. In the same study, the administration of the Activin A inhibitor Folistatin resulted in attenuation of the histological damage of the ARDS-afflicted rat lung.
The precise role of Activin A/Folistatin in acute respiratory failure associated with acute lung inflammatory pathology has not been elucidated yet. Therefore, the purpose of the present, observational study is to investigate the role of Activin A/Folistatin in respiratory failure due to ARDS and/or ventilator-associated pneumonia (VAP), also in relation with other biochemical markers, such as cytokines and surfactant-related proteins.

Start Date01 Dec 2013

Sponsor / Collaborator

National & Kapodistrian University of Athens

[+1]

100 Clinical Results associated with Academy of Athens

0 Patents (Medical) associated with Academy of Athens

1,594

Literatures (Medical) associated with Academy of Athens

01 Sep 2025·METABOLISM-CLINICAL AND EXPERIMENTAL

Exercise mitigates liver senescence but does not outmatch dietary restriction in obesity-related MASLD

Article

Author: Giannousi, Eirini ; Philippou, Anastassios ; Legaki, Aigli-Ioanna ; Chatzigeorgiou, Antonios ; Agrogiannis, George ; Papadopoulos, Grigorios ; Kotsinas, Athanassios ; Papadopetraki, Argyro ; Moustogiannis, Athanasios ; Pantelis, Pavlos ; Moustakas, Ioannis I ; Evangelou, Konstantinos ; Gorgoulis, Vassilis G ; Veroutis, Dimitris ; Koutsilieris, Michael ; Katsarou, Angeliki

BACKGROUND:

The present study aims at deciphering the individual or combined benefits of aerobic exercise and dietary restriction on liver senescence, a state characterized by cell cycle arrest and simultaneous resistance to apoptosis, which is considered an established hallmark of metabolic dysfunction-associated steatotic liver disease (MASLD).

METHODS:

C57BL6 mice were subjected to a normal diet (ND) for 20 weeks or a high-fat diet (HFD) supplemented with 5 % High-fructose Corn Syrup (HFCS) for 12 weeks, followed by eight-week interventions, including dietary restriction (DR), aerobic exercise (EX), a combination of both (DREX) or continuation of a HFD-HFCS diet without intervention. Biomarkers of senescence were analyzed in terms of their liver mRNA expression levels, while GL13 and p21^WAF1/CIP1 immunohistochemical stainings were conducted to examine the levels of senescence-associated lipofuscin and p21^WAF1/CIP1 respectively, to finally investigate their relationship with the grade of hepatic steatosis and fibrosis observed in the studied mice.

RESULTS:

DR and DREX groups exhibited significantly reduced features of obesity and MASLD-related hepatic steatosis and fibrosis, to a greater extent than the respective amelioration driven by aerobic exercise only in HFDEX animals. A statistically significant increase of mRNA expression was detected for cyclin-dependent kinase p21^WAF1/CIP1 in HFD livers as compared to ND, which was also reversed upon DR-inclusive interventions. Immunohistochemical stainings for GL13 and p21^WAF1/CIP1, as well as for p16^INK4A confirmed the aforementioned alterations of p21^WAF1/CIP1 at the tissular level while also revealed a p16^INK4A elevation in HFD livers which was reversed only upon DR/DREX.

CONCLUSION:

Liver senescence is responsive both to exercise and dietary restriction, but its amelioration in the context of MASLD is more robust upon DR-inclusive interventions.

21 Aug 2025·JOURNAL OF PHYSICAL CHEMISTRY B

Thermodynamics and Kinetics of the Deintercalation of a Novel Anthracycline from Double-Stranded Oligonucleotide DNA

Article

Author: Theodorou, Doros N. ; Mikaelian, Georgios ; Megariotis, Grigorios ; Sarimveis, Haralambos

We present an in silico study of the deintercalation of berubicin from two double-stranded oligonucleotide DNA sequences using well-tempered metadynamics (WT-MetaD), an enhanced sampling method widely employed for biomolecular systems. In our recent study (Mikaelian, G. J. Phys. Chem. B 2024, 128(26), 6291-6307), the thermodynamics of DNA-berubicin complexes in the intercalated state was examined in detail. Continuing this study here, we focus on the thermodynamics and kinetics of deintercalation, undertaking a rigorous analysis of individual stages in its mechanism. The Gibbs energy surface is first calculated as a function of two collective variables (used in prior studies of anthracyclines), followed by an estimation of deintercalation times. These deintercalation times are comparable to─or even exceed─those of clinically established anthracyclines in widespread therapeutic use. Our simulations reveal that the deintercalation mechanism involves two stable states─the intercalated state and the minor groove-bound state─as well as a reshuffling state. This three-step mechanism that emerges is supported by other published studies concerning DNA-anthracycline complexes. The rate-limiting step of the deintercalation mechanism is the transition from the intercalated to the reshuffling state, and the applied method allows a detailed description of it. Each state is described in terms of various properties, whose values are consistent with published computational and experimental studies on the interactions of other anthracyclines with DNA.

01 Aug 2025·JOURNAL OF HEPATOLOGY

Successful AAV8 gene therapy on hepatic ex situ machine perfusion for mitochondrial neurogastrointestinal encephalomyopathy

Article

Author: Kaser, Arthur ; Chinnery, Patrick F ; Swift, Lisa ; Malam, Yogeshkumar ; Sampaziotis, Fotios ; Kosmoliaptsis, Vasilis ; Foukaneli, Dora ; Hosgood, Sarah A ; Gelson, William Th ; Spiers, Harry Vm ; Trauner, Michael ; Emmett, Erin ; Scaravaglio, Miki ; Brevini, Teresa ; Reynolds, Helen ; Thompson, Richard J ; See, Teik Choon ; Athanasiadis, Emmanouil ; Gorgoulis, Vassilis G ; Pettigrew, Gavin J ; Heslop, James ; Andreatta, Brock ; Allinson, Kieren ; van den Ameele, Jelle ; Gibbs, Paul ; Stopforth, Richard J ; Fuchs, Claudia D ; Paterson, Anna L ; Vakeeswarasarma, Vitushan ; Marti, Ramon ; Pantelis, Pavlos ; Ong, John ; Webb, Gwilym J ; Butler, Andrew J ; Duckworth, Adam ; Watson, Christopher Je ; Jovanovic, Emilija ; Cacciottolo, Tessa M

Ex situ normothermic machine perfusion (NMP) is rapidly emerging as a novel platform for testing therapeutics in human donor livers. Recently perfusion of explanted patient livers was achieved, raising the possibility of using these diseased organs to increase the fidelity and resolution of drug testing and development. Here, we provide proof-of-principle for the feasibility of this approach in the context of gene therapy. We report the first successful administration of AAV8 treatment in the explanted liver of a 34-year-old patient with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), using machine perfusion. MNGIE is caused by mutations in the thymidine phosphorylase (TYMP) gene, leading to nucleoside accumulation. The patient's liver was split into anatomical left and right lobes and perfused using separate machine perfusion devices. Prior to treatment, nucleoside accumulation was observed in the perfusate of both lobes, recapitulating the cardinal feature of MNGIE. An AAV8 vector carrying the human TYMP gene was administered in the left lobe with the right serving as control. AAV8 gene therapy resulted in successful vector uptake, with complete nucleoside clearance within 6 days of administration. Our results constitute the first demonstration for the efficacy of gene therapy for MNGIE in a human organ and provide proof-of-principle for using machine perfusion as a new strategy for disease modelling and testing novel therapeutics, e.g. gene therapy, in patient's explanted livers.

News (Medical) associated with Academy of Athens

07 Dec 2023

·www.businesswire.com

PlumCare and Fabric Genomics Announce a Strategic Partnership to Integrate the Fabric AI Platform with PlumCare’s FirstSteps™ Newborn Genome Screening Program in Greece

ATHENS, Greece & OAKLAND, Calif.--( BUSINESS WIRE )-- PlumCare RWE and Fabric Genomics have partnered to deliver the Fabric AI platform with the PlumCare RWE FirstSteps newborn genome screening program in Greece. The goal of FirstSteps , a population health initiative, is to be able to screen every newborn in Greece by whole genome sequencing within the next five years. The FirstSteps program will leverage the power of the Fabric AI platform to offer rapid, accurate clinical genomic variant interpretation for whole genome sequencing (WGS) of screened newborns in Greece. Fabric AI technology for interpretation of the human genome, powered by the Fabric GEM AI algorithm, will be adapted into the FirstSteps clinical support tool, empowering clinicians to provide timely medical intervention for patients with rare genetic diseases in Greece. “The introduction of the Fabric AI platform into the national population health initiative FirstSteps represents an extension of a longstanding partnership between the two companies, and it will help create an ecosystem to enable drug discovery and development for rare diseases,” said Petros Tsipouras, MD, Managing Partner of PlumCare RWE and Scientific Director of FirstSteps. Professor Dimitris Thanos, PhD, Member of the Academy of Athens and Vice Chairman of the Scientific Advisory Board of FirstSteps said, “Bringing the Fabric AI platform to support and speed up our variant interpretation process will enhance the overall performance of the FirstSteps program and help improve the lives of patients with rare genetic diseases in Greece and around the world.” “We are excited to extend our partnership with PlumCare RWE into the new FirstSteps program to bring our genomics AI analysis technology to Greece to support their precision medicine initiative and additionally, to foster an innovation hub in Greece. This partnership will enable us to expand our reach to Europe and improve outcomes for patients,” said Martin Reese, PhD, Co-Founder and CEO of Fabric Genomics. Fabric Genomics is proud to support the innovative PlumCare team to improve screening for babies in Greece by customizing its universal platform to the specific needs required in the national FirstSteps program. This partnership comes on the heels of Fabric Genomics’ previously announced successful partnerships with Rady Children’s Institute for Genomic Medicine and with the Broad Institute of MIT and Harvard offering affordable clinical whole genome analysis in its effort to bring better genomics-based healthcare to all patients. About PlumCare RWE PlumCare RWE is at the forefront of biotechnology and healthcare data, harnessing the power of real-world evidence and multi-omics analysis to provide actionable insights that enhance both population health and individual family well-being. Our commitment to precision medicine is evident through our comprehensive services that include early screening, accurate diagnosis, and timely interventions, all aimed at fostering better health outcomes for families. We are dedicated to advancing the discovery and development of novel treatments for genetic diseases within a secure, privacy-compliant, and trusted research environment. Our European headquarters in Athens, Greece is home to our wholly-owned subsidiary RealGenix and the FirstSteps Greece national genome screening initiative. At PlumCare RWE, we are passionate about creating a healthier future for families through innovation and personalized care. For more information visit plumcare.com and our LinkedIn page. About Fabric Genomics Fabric Genomics is transforming healthcare through its AI-driven interpretation of the human genome. The company provides organizations with end-to-end clinical sequence analysis solutions that include the Fabric Enterprise software platform and expert clinical interpretation services needed to scale genetic testing. At the core of our platform is a suite of sophisticated AI algorithms and data knowledge systems that turn genomic data into expert clinical insights. Headquartered in Oakland, California, Fabric Genomics supports clinical applications across a variety of use cases including rare disease, oncology, cardiovascular, neurological and women’s health. To learn more, visit fabricgenomics.com and follow us on X (Twitter) and LinkedIn .

100 Deals associated with Academy of Athens

100 Translational Medicine associated with Academy of Athens

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 02 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

BRF110 ( RXRA )	Parkinson Disease More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis